Media headlines about Crispr Therapeutics (NASDAQ:CRSP) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Crispr Therapeutics earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.6272309060317 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Better Buy: Editas Medicine, Inc. vs. CRISPR Therapeutics (finance.yahoo.com)
- Long-Term Outlook For Crispr Therapeutics: Sept. 5, 2018 (seekingalpha.com)
- Forget CRISPR Therapeutics: Vertex Pharmaceuticals Incorporated Is a Better Biotech Stock (finance.yahoo.com)
- Global CRISPR Genome Editing Market Will Grow USD 4271.0 Million by 2024: Zion Market Research (globenewswire.com)
- Pivoting Three Stocks: Electronic Arts Inc. (NASDAQ:EA), Adobe Systems Incorporated (NASDAQ:ADBE), CRISPR … (thestreetpoint.com)
Shares of NASDAQ CRSP opened at $50.14 on Friday. Crispr Therapeutics has a twelve month low of $16.16 and a twelve month high of $73.90. The stock has a market capitalization of $2.37 billion, a price-to-earnings ratio of -29.32 and a beta of 3.40.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, August 8th. The company reported ($0.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.19). Crispr Therapeutics had a negative net margin of 245.57% and a negative return on equity of 39.58%. The business had revenue of $1.09 million during the quarter, compared to analyst estimates of $1.47 million. equities research analysts anticipate that Crispr Therapeutics will post -2.89 earnings per share for the current fiscal year.
Several equities research analysts recently weighed in on the stock. Citigroup reduced their price objective on shares of Crispr Therapeutics from $51.00 to $50.00 and set a “neutral” rating for the company in a report on Friday, August 24th. Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 10th. Chardan Capital reaffirmed a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a report on Wednesday, August 8th. BidaskClub downgraded shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 26th. Finally, ValuEngine raised shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $65.78.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Thursday, July 5th. The shares were sold at an average price of $62.00, for a total value of $465,000.00. Following the completion of the sale, the director now directly owns 5,816 shares of the company’s stock, valued at approximately $360,592. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Pablo J. Cagnoni sold 5,816 shares of the company’s stock in a transaction dated Tuesday, July 3rd. The shares were sold at an average price of $62.00, for a total transaction of $360,592.00. Following the completion of the sale, the director now directly owns 5,816 shares of the company’s stock, valued at $360,592. The disclosure for this sale can be found here. 37.70% of the stock is currently owned by corporate insiders.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Featured Story: Hedge Funds
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.